OVERVIEW

 

First Wave BioPharma, Inc. is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

First Wave is currently advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its three proprietary technologies – capeserod, a selective 5-HT4 receptor partial agonist for GI indications; the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-inflammatory properties.

 

logo ICO

CONTACT

777 Yamato Road Suite 502
Boca Raton, FL 33431
(561) 589-7020
info@firstwavebio.com

SOCIAL MEDIA